Levomefolate (calcium)

CAT: 0804-HY-17383-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-17383-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Levomefolate calcium is an orally active, BBB-penetrable and active form of folic acid. Levomefolate calcium can be used as a food supplement for folic acid and in the research of neural tube defect diseases[1][2][3][4].
CAS Number
[151533-22-1]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antifolate
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Levomefolate-calcium.html
Purity
99.46
Solubility
H2O : 4.4 mg/mL (ultrasonic; warming)
Smiles
O=C([O-])CC[C@@H](C([O-])=O)NC(C1=CC=C(NC[C@@H]2N(C)C3=C(N=C(N)NC3=O)NC2)C=C1)=O.[Ca+2]
Molecular Formula
C20H23CaN7O6
Molecular Weight
497.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Wiesinger H, Eydeler U, Richard F, et al. Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone. Clin Drug Investig. 2012 Oct 1;32 (10) :673-84.|[2]Hartmut Blodea, Christine Klippingb, Frank Richardc, et al. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. Contraception.2012, 85 (2), :177-184|[3]Rapkin RB, Creinin MD. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opin Pharmacother. 2011 Oct;12 (15) :2403-10. doi: 10.1517/14656566.2011.610791.|[4]Levomefolic_acid
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Nov 18.|Oncogene. 2025 May;44 (16) :1078-1092.